Nanobiotix S.A. (NBTX) Stock Price & How to Invest

Last updated November 2026

Short answer

NBTX is Nanobiotix, a clinical-stage French nanomedicine company whose lead asset NBTXR3 (JNJ-1900) is a radioenhancer partnered globally with Johnson & Johnson, so buying it is a bet on late-stage cancer trial readouts rather than on product profits. It trades as a pre-approval, binary-outcome biotech, meaning the position lives or dies on Phase 3 data and regulatory decisions. As of November 20, 2026 the ADSs closed near $26.80 (market value ~$1.37 billion), up ~21% for the year and ~32% over twelve months but still down ~35% over three months.

NBTX stock price

As of 2026-11-20, Nanobiotix S.A. (NBTX) last closed at $26.50, up 26.6% over the past year. Over the past 52 weeks it has traded between $19.97 and $55.07.

NBTX last close
$26.50
1 day
-2.98%
1 month
+2.59%
1 year
+26.61%
52-week range
$19.97 to $55.07
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Nanobiotix S.A.'s investor relations page. Walnut is informational, not investment advice.

NBTX key stats

At $26.50 on November 20, 2026, Nanobiotix S.A. (NBTX) has a market cap of $1.4B.

Market cap
$1.4B
Beta
0.54

Market cap, P/E and yield are measured at the $26.50 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Nanobiotix S.A. (NBTX)?

The last two weeks for Nanobiotix S.A., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • NBTX closed at $26.50 on November 20, 2026, down 13.6% over the past five trading days (from $30.66).
  • On November 12, 2026, Nanobiotix S.A. filed a current report (6-K) with the SEC. Read the 6-K on sec.gov

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

What does Nanobiotix S.A. (NBTX) do?

Nanobiotix S.A. is a clinical-stage nanomedicine company headquartered in France and dual-listed on Nasdaq (as American Depositary Shares under NBTX) and Euronext Paris. Its lead product candidate, NBTXR3 (also called JNJ-1900), is a radioenhancer: injectable nanoparticles that are placed directly into a tumor and, when activated by standard radiotherapy, are designed to boost the radiation's tumor-killing effect. In late 2023 the company signed a global license and collaboration with Johnson & Johnson's Janssen unit, which now sponsors and operates the registrational Phase 3 NANORAY-312 study in head and neck cancer and broader development across other solid tumors.

As a pre-revenue-product biotech, Nanobiotix has no approved drug and its reported revenue comes largely from the J&J agreement rather than from selling a product, so the investment picture is defined by pipeline milestones and cash runway rather than earnings. The bull case rests on NBTXR3 succeeding in head and neck cancer plus expansion signals in lung and other tumors, unlocking large milestone and royalty payments from J&J. The bear case is the standard clinical-biotech risk: a failed or delayed Phase 3, further dilution, and a valuation (roughly $1.37 billion on November 20, 2026, down from about $1.5 billion in mid-2026) that already prices in meaningful clinical success years before any approval.

The first half of 2026 showed what the business looks like without one-off items: revenue and other income fell to about 5.6 million euros from 26.6 million euros a year earlier (the 2025 figure included a 21.2 million euro non-cash benefit from transferring NANORAY-312 sponsorship to J&J), and the net loss widened to about 34.3 million euros. Cash rose to about 110.9 million euros at June 30, 2026 after the May offering, and in October 2026 the company named Arnd Christ as Chief Financial Officer. On October 24, 2026, at the ESMO meeting in Madrid, it presented final Phase 1 data in anti-PD-1-resistant melanoma that lifted the shares.

What's driving Nanobiotix S.A. (NBTX)?

1. Johnson & Johnson partnership

J&J's Janssen unit holds a global license to NBTXR3 and now covers most costs of the registrational Phase 3 program, validating the science and de-risking spend. The deal carries potential milestone payments reported around $1.77 billion for the first programs plus royalties, so success would deliver large non-dilutive cash flows. Having a large-cap pharma sponsor also lends operational scale that a small biotech could not fund alone.

2. NANORAY-312 head and neck readout

NANORAY-312 is the registrational Phase 3 study in locally advanced head and neck squamous cell carcinoma in platinum-ineligible patients, now J&J-sponsored, and its data is the single biggest catalyst for the stock. An FDA-cleared protocol amendment removed the interim analysis and changed the final analysis to include fewer events so it can be conducted sooner; the September 2026 half-year update did not give a specific readout date. A positive result would open a U.S. regulatory filing and a first potential approval.

3. Pipeline expansion beyond head and neck

Early Phase 2 CONVERGE data in stage 3 inoperable non-small cell lung cancer showed an encouraging overall response rate (85.7 percent, six of seven patients) when NBTXR3 was combined with chemoradiotherapy and immunotherapy. In September 2026 the company reported complete Phase 1 results from an MD Anderson study in inoperable, recurrent lung cancer: 79% one-year locoregional control in 24 patients, with no dose-limiting toxicities and no grade 3 or higher treatment-related adverse events. In October 2026 final Phase 1 data in 24 patients with anti-PD-1-resistant advanced cutaneous melanoma, treated with NBTXR3 and radiotherapy followed by nivolumab or pembrolizumab, showed a 41.7% overall response rate (10 of 24, including 4 complete responses), a 75% disease control rate, median progression-free survival of 6.9 months and median overall survival of 17.8 months, with no new safety signals. The study was single-arm and small, and investigators said randomized trials are needed. Additional tumor types and an Asia collaboration (LianBio) broaden the addressable opportunity. Each new indication is optionality layered on top of the core head and neck program.

4. Extended cash runway

After a roughly 86 million euro follow-on offering in May 2026 on top of prior royalty financing, cash stood at about 110.9 million euros at June 30, 2026, and the company reiterated in September 2026 that it expects cash to fund operations into 2029. A longer runway reduces the near-term risk of a forced, deeply dilutive raise ahead of key data. It gives Nanobiotix room to reach key readouts without an urgent financing overhang, though Yahoo Finance also lists about $107 million of debt, largely tied to the earlier royalty financing.

What are the risks to Nanobiotix S.A. (NBTX)?

The dominant risk is clinical and binary: NBTXR3 remains unapproved, and a failed or delayed NANORAY-312 Phase 3 could erase much of the equity value in a single day. As a clinical-stage biotech, Nanobiotix funds itself through partnership payments and equity raises, so continued losses and further share dilution are likely until (and unless) a product is approved. The valuation of roughly $1.37 billion (November 2026) still embeds substantial expectation of success, leaving little margin for disappointment. Concentration is acute because a large share of value depends on one molecule and one partner, so a strategic shift by J&J would be highly damaging. The NANORAY-312 amendment that cut the interim analysis and reduced the planned number of events speeds the readout but could affect the trial's statistical power. Being a foreign issuer listed via ADS also adds currency, reporting-timing, and liquidity considerations for U.S. holders. The stock's ~35% drop over the three months to November 20, 2026, even after a bounce on early-stage melanoma data, shows how sharply sentiment can move without a registrational result. Early single-arm data, like the melanoma study, can move the shares but does not establish efficacy.

What is the Nanobiotix S.A. (NBTX) forecast?

3 analysts publish price targets on NBTX, averaging $53.36 as of November 2026, or +101.4% against the $26.50 share price on November 20, 2026. The published targets run from $29.57 to $68.66, a wide spread, and the ratings split 4 buy, 1 hold, 0 sell. Over the last six months there has been 1 raise and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full NBTX forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is NBTX a buy or a sell?

We give no verdict on Nanobiotix S.A.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Johnson & Johnson partnership. J&J's Janssen unit holds a global license to NBTXR3 and now covers most costs of the registrational Phase 3 program, validating the science and de-risking spend. The most optimistic published target, $68.66, assumes this works close to its best case.

The case against. The dominant risk is clinical and binary: NBTXR3 remains unapproved, and a failed or delayed NANORAY-312 Phase 3 could erase much of the equity value in a single day. The most pessimistic target, $29.57, is roughly what NBTX is worth if this bites instead.

Read the full bull and bear case on NBTX, including what would have to change to break either one. Walnut is not an investment adviser.

Has Nanobiotix S.A. (NBTX) split its stock?

No. Nanobiotix S.A. (NBTX) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Nanobiotix S.A. (NBTX) valued?

Market cap, P/E and dividend yield at today's price are in the NBTX key stats above. The business figures below come from Nanobiotix S.A.'s reported results as of November 2026 and change when it next reports.

  • Revenue (TTM): ~$11.5 million (largely J&J-agreement, non-product)
  • Revenue growth: ~-79% year over year in H1 2026 (EUR 5.6M vs EUR 26.6M, which had a one-off item)
  • Net loss (TTM): ~$53 million
  • Net loss (H1 2026): ~EUR 34.3M (EUR 0.70 per share)
  • Cash (June 30, 2026): ~EUR 110.9M after the ~EUR 86.1M May 2026 raise
  • Cash runway guidance: ~into 2029

As of November 2026: Standard price-to-earnings valuation does not apply because Nanobiotix is pre-approval and its reported revenue stems mostly from the J&J agreement rather than product sales. The market instead prices the probability-weighted value of NBTXR3 across head and neck, lung, melanoma and other tumors, net of dilution risk; that value fell from roughly $1.5 billion in mid-2026 to about $1.1 billion by mid-October, then recovered to ~$1.37 billion by November 20 after the melanoma data. The three analysts with targets on Yahoo Finance averaged about $53, roughly double the current price, a gap typical of binary-outcome biotechs.

Who competes with Nanobiotix S.A. (NBTX)?

Radiation-enhancement and radiotherapy technology

Companies developing agents or devices that make radiotherapy more effective compete for the same clinical niche NBTXR3 targets. This includes radiosensitizer and radiopharmaceutical developers and established radiation-oncology equipment and technique providers, which set the standard of care NBTXR3 must beat or complement.

Head and neck and solid-tumor oncology developers

In head and neck cancer specifically, NBTXR3 must show benefit against or alongside immunotherapies (such as PD-1 and PD-L1 checkpoint inhibitors) and cetuximab-based regimens marketed by large pharma. These agents define existing treatment paradigms and represent both competition and potential combination partners.

Clinical-stage nanomedicine and oncology biotechs

Other small and mid-cap clinical-stage oncology and nanoparticle-drug companies compete for investor capital, trial sites, and pharma partnerships. Investors weighing NBTX often compare it against this broader cohort of single-asset, catalyst-driven biotechs with similar binary risk profiles.

What stocks are similar to Nanobiotix S.A. (NBTX)?

Other names that sit close to NBTX: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Nanobiotix S.A. (NBTX)

There are three common ways to get NBTX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so NBTX sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where NBTX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Nanobiotix S.A. (NBTX)

Nanobiotix is a J&J-partnered, single-asset oncology story where the entire thesis rides on NBTXR3 trial readouts and a still-distant potential approval. The swings are large: the ADSs traded between ~$19 and ~$57 over the past year, fell sharply into mid-October 2026, then recovered part of that after melanoma data in late October, with no approved product or earnings to anchor the price.

More on Nanobiotix S.A. (NBTX)

Whether NBTX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is NBTX a buy or a sell?, and where the stock could go from here in the NBTX stock forecast.

For income investors, whether NBTX pays a dividend and how the payout looks is covered in does NBTX pay a dividend? And to weigh NBTX against a peer, read the full side-by-side comparisons: NBTX vs PD and NBTX vs MRNA.

Wondering how NBTX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Nanobiotix S.A.

Ask Walnut's AI anything about NBTX and see how it fits what you own.

FAQ

What does Nanobiotix (NBTX) actually do?

+

It is a clinical-stage nanomedicine company developing NBTXR3, injectable nanoparticles placed inside a tumor that are activated by standard radiotherapy to enhance the radiation's cancer-killing effect. It has no approved product yet and is focused on late-stage cancer trials.

What is the Johnson & Johnson partnership?

+

J&J's Janssen unit holds a global license to NBTXR3 (branded JNJ-1900) and now sponsors and funds most of the registrational Phase 3 program. The collaboration includes potential milestone payments (reported around $1.77 billion for first programs) plus royalties if the drug is approved and sold.

What is NANORAY-312?

+

NANORAY-312 is the registrational Phase 3 trial testing NBTXR3 in locally advanced head and neck squamous cell carcinoma in patients who cannot take platinum chemotherapy. It is J&J-sponsored, was amended with FDA clearance to remove the interim analysis and run the final analysis sooner on fewer events, and its data is the single most important catalyst for the stock. No specific readout date was given in the September 2026 update.

Is NBTX profitable?

+

No. It reported a net loss of roughly 24 million euros for full-year 2025 and about 34.3 million euros for the first half of 2026 alone, and its revenue comes mainly from the J&J agreement rather than product sales. As a pre-approval biotech it is expected to keep operating at a loss until a product reaches the market.

How much cash does Nanobiotix have?

+

It reported about 110.9 million euros in cash at June 30, 2026, up from 52.8 million euros at the end of 2025 after a roughly 86 million euro equity raise in May 2026. Including prior royalty financing, management guides to a cash runway into 2029.

Why is NBTX considered high risk?

+

Its value is concentrated in one molecule (NBTXR3) and one main partner (J&J), and it is pre-approval, so a failed or delayed Phase 3 readout could sharply reduce the share price. Ongoing losses also mean continued dilution risk until a product is approved.

Is NBTX a US or foreign company?

+

Nanobiotix is a French company headquartered in Paris. Its US-listed shares trade on Nasdaq as American Depositary Shares under the ticker NBTX, while its ordinary shares also trade on Euronext Paris, which adds currency and reporting-timing considerations for US investors.

How could I research NBTX in Walnut?

+

You can add NBTX to a thematic basket, connect your brokerage read-only, and use Walnut's AI assistant to review its pipeline milestones, cash runway, and how it fits your targets. Walnut is not an investment adviser and does not tell you whether to buy or sell; it helps you track and understand your positions.

How did Nanobiotix do in the first half of 2026?

+

For the six months to June 30, 2026, Nanobiotix reported revenue and other income of about 5.6 million euros, down from 26.6 million euros a year earlier, when a one-off 21.2 million euro non-cash item from the J&J sponsorship transfer inflated the figure. The net loss widened to about 34.3 million euros (0.70 euros per share), while R&D and SG&A spending both declined. Cash ended the period at about 110.9 million euros.

How has NBTX stock performed in 2026?

+

As of the November 20, 2026 close near $26.80, NBTX was up ~21% year to date and ~32% over one year. The ride was rough: the ADSs fell ~35% over the three months to that date and ~9% over the final month, after a slide into mid-October and a partial rebound on melanoma data presented October 24. Its 52-week range runs from about $19 to $57, which shows how volatile a single-asset, pre-approval biotech can be. Past performance does not predict future returns.

What did the October 2026 melanoma data show?

+

On October 24, 2026, at the ESMO Annual Meeting in Madrid, Nanobiotix presented final results from a Phase 1 study of NBTXR3 (JNJ-1900) activated by radiotherapy and followed by nivolumab or pembrolizumab in 24 patients whose advanced cutaneous melanoma had stopped responding to anti-PD-1 drugs. The overall response rate was 41.7% (10 of 24, including 4 complete responses), disease control was 75%, median progression-free survival was 6.9 months and median overall survival was 17.8 months, with no new safety signals. Responses were also seen in some non-injected lesions (3 of 10 evaluable). The study had no control arm, so it signals activity rather than proving benefit, and investigators said randomized trials are warranted. The ADSs rose on the news.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Nanobiotix S.A.'s investor relations page or your broker before making investment decisions.